Sitagliptin Rivals Glimepiride For Glycemic Control With Less Hypoglycemia And No Weight Gain
Links shared publicly online about this topic.
- 860total visits
Sitagliptin Rivals Glimepiride For Glycemic Control With Less Hypoglycemia And No Weight Gain
The addition of the highly selective, once-daily dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin (Januvia), compared with glimepiride (Amaryl), to background metformin therapy provides similar
View full resource at medicalnewstoday.com
Tags: Diabetes Type 2 Medication, Diabetes Medication, Low Blood Sugar, Amaryl, Glucophage, Januvia
Most Recently Shared on September 20, 2010 at 6:05 pm By:
Sitagliptin Rivals Glimepiride For Glycemic Control With Less Hypoglycemia And No Weight Gain http://mnt.to/3K3V #diabetes
Also Shared By:
Sitagliptin Rivals Glimepiride For Glycemic Control With Less Hypoglycemia And No Weight Gain | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com
keyvive.com — “Sitagliptin Rivals Glimepiride For Glycemic Control With Less Hypoglycemia And No Weight Gain | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com” View full resource at keyvive.com
Most Recently Shared on September 20, 2010 at 9:50 pm By:
Sitagliptin Rivals Glimepiride For Glycemic Control With Less Hypoglycemia And No Weight Gain… http://goo.gl/fb/1j6nu
Advertisement
MNT Health News
@mnt_healthnews
Sitagliptin Rivals Glimepiride For Glycemic Control With Less Hypoglycemia And No Weight Gain http://mnt.to/3K3V #healthnews
1 year ago...